Loading company…
TherOx develops SSO2 Therapy for patients with ischemic heart conditions.
Founded in 1995 and based in Irvine, US, TherOx develops cardiac treatments, including its FDA-approved SuperSaturated Oxygen (SSO2) Therapy. The catheter-based system is intended to reduce heart muscle damage in patients with ST-Elevation Myocardial Infarction following angioplasty. The company raised USD 15 million in Venture Debt in May 2018, led by ZOLL Medical.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in